论文部分内容阅读
目的观察替吉奥(S-1)胶囊联合奥沙利铂注射液(L-OHP)治疗进展期胃癌(AGC)的临床疗效及不良反应。方法对符合入组条件的59例进展期胃癌患者,分为治疗组及对照组,治疗组采用S-1联合奥沙利铂方案治疗,对照组采用OFL(奥沙利铂联合亚叶酸钙和5-氟尿嘧啶)方案治疗。结果治疗组CR4例(13.3%),PR10例(33.3%),SD14例(46.7%),PD2例(6.7%),RR46.6%,DCR93.3%;对照组CR0例,PR6例(20.7%),SD15例(51.7%),PD8例(27.6%),RR20.7%,DCR72.4%。两组对比有效率和疾病控制率有统计学差异(P<0.05)。治疗组不良反应发生率明显较对照组低(P<0.05)。结论替吉奥胶囊联合奥沙利铂注射液方案治疗进展胃癌的疗效可靠、毒副作用较轻,不良反应可以耐受,是治疗晚期胃癌,特别是年龄较大、一般状态较差的患者的安全有效的治疗方案。
Objective To observe the clinical efficacy and side effects of tioguanoside (S-1) capsule and oxaliplatin injection (L-OHP) in the treatment of advanced gastric cancer (AGC). Methods Fifty-nine patients with advanced gastric cancer who met the inclusion criteria were divided into treatment group and control group. The treatment group was treated with S-1 combined with oxaliplatin and the control group was treated with OFL (oxaliplatin combined with leucovorin and 5-fluorouracil) regimen. Results CR4 cases (13.3%), PR10 cases (33.3%), SD14 cases (46.7%), PD2 cases (6.7%), RR46.6% and DCR93.3% %), SD15 (51.7%), PD8 (27.6%), RR20.7% and DCR72.4%. There was a significant difference between the two groups in the rate of control and disease control (P <0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion The treatment of advanced gastric cancer with TEGO capsule combined with oxaliplatin injection is reliable, with less toxic side effects and tolerable adverse reactions. It is a safe and effective method for the treatment of advanced gastric cancer, especially in the older and generally poor patients Effective treatment options.